26.06.2018 • News

Juniper Pharma Services in Lab Expansion

Juniper Pharma Services in Lab Expansion
Juniper Pharma Services in Lab Expansion

Juniper Pharma Services (JPS), a Nottingham, England-based contract development and Manufacturing Organisation (CDMO) specializing in the development of challenging small molecules, said it is “significantly” expanding its UK-based drug development and clinical trial manufacturing facilities.

The extension, planned to be completed this summer, will provide four additional process development laboratories at Nottingham that the company said will improve output and efficiency of its development and clinical manufacturing operations.

JPS said the new labs will enable it to work with an ever-growing client base to transform poorly soluble and difficult to formulate molecules into successful products. It said the expansion will also ensure that processing and formulation work is scalable, thus facilitating the efficient manufacture of stability and clinical batches.

Nikin Patel, president of Juniper Pharma Services, said the company continues to explore opportunities to extend its service offerings to meet the evolving requirements of its market and clients.

 

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.